サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がん幹細胞の世界市場：市場規模 - がん別、作用機序別、移植別、用途別、エンドユーザー別、地域別展望、競合戦略、セグメント別予測（～2032年）
市場調査レポート
商品コード
1170429

がん幹細胞の世界市場：市場規模 - がん別、作用機序別、移植別、用途別、エンドユーザー別、地域別展望、競合戦略、セグメント別予測（～2032年）

Cancer Stem Cells Market Size- By Cancer, By Mode Of Action, By Transplantation, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 226 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
がん幹細胞の世界市場：市場規模 - がん別、作用機序別、移植別、用途別、エンドユーザー別、地域別展望、競合戦略、セグメント別予測（～2032年）
出版日: 2022年12月02日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 226 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のがん幹細胞の市場規模は、2032年までに26億8,000万米ドルに達し、CAGRで10.29%の成長が予測されています。

市場拡大の主な要因は、世界のがん罹患率の上昇です。ヒトのDNAを改変する遺伝子工学と、幹細胞から三次元構造の組織を作り出すオルガノイド技術の出現は、COVID-19の間の幹細胞研究において大きく前進した2つの要素で、世界のがん幹細胞市場に好影響を与えました。

当レポートでは、世界のがん幹細胞市場について調査し、市場力学、市場変数と展望、がん・作用機序・移植・用途・最終用途・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

  • 調査範囲
  • 市場セグメント分析

第2章 調査手法

  • 調査データソース
  • 市場規模の推定
  • データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因、抑制要因、機会、および課題分析
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 世界のがん幹細胞市場におけるCOVID-19の影響

第5章 市場変数と展望

  • SWOT分析
    • 強み
    • 弱み
    • 機会
    • 脅威
  • PESTEL分析
    • 政治情勢
    • 経済情勢
    • 社会情勢
    • 技術情勢
    • 環境情勢
    • 法的情勢
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入者の脅威
    • 競合企業間の敵対関係
  • ヒートマップ分析

第6章 世界のがん幹細胞市場：がん別（2019年～2032年（100万米ドル））

  • 急性白血病
  • 再生不良性貧血
  • 慢性リンパ性白血病
  • 骨粗鬆症

第7章 世界のがん幹細胞市場：作用機序別（2019年～2032年（100万米ドル））

  • 標的とするがん幹細胞
    • 抗CSC治療薬別
    • 製品
  • 幹細胞ベースのがん治療
    • 自家SC移植
    • 同種SC移植

第8章 世界のがん幹細胞市場：移植別（2019年～2032年（100万米ドル））

  • 同種幹細胞治療
  • 自家幹細胞治療

第9章 世界のがん幹細胞市場：用途別（2019年～2032年（100万米ドル））

  • 血液がん
  • 乳がん
  • 子宮頸がん
  • 大腸がん
  • 肺がん
  • 前立腺がん

第10章 世界のがん幹細胞市場：最終用途別（2019年～2032年（100万米ドル））

  • 細胞バンク・組織バンク
  • 病院・手術用検査室
  • 製薬企業・バイオメディカル企業

第11章 世界のがん幹細胞市場：地域別（2019年～2032年（100万米ドル））

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • サウジアラビア王国
    • アラブ首長国連邦
    • その他の中東・アフリカ

第12章 企業プロファイル

  • AbbVie Inc.
    • 企業概要
    • 財務展望
    • 製品概要
    • 最近の開発
  • Advanced Cell Diagnostics Inc.
  • Bionomic
  • BioNTech
  • BioTime Inc.
  • Caladrius Biosciences Inc.
  • Celgene Corp.
  • ExCellThera
  • Gamida Cell
  • Irvine Scientific
  • Lonza
  • MacroGenics Inc.
  • Menarini Group
  • Merck KGaA
  • Mereo BioPharma
  • Miltenyi Biotec
  • PromoCell GmbH
  • Propanc Biopharma
  • Silicon Biosystems
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.
  • VIaCyte Inc.
目次
Product Code: HLCA2220

Global Cancer Stem Cells Market Overview:

According to SPER Market Research, the Global Cancer Stem Cells Market is estimated to reach USD 2.68 billion by 2032 with a CAGR of 10.29%.

The tumour's other cell types are produced by the cancer cell, which has the capacity to divide and grow continuously. Cancer stem cells are believed to oversee tumour development, metastasis, and recurrence. These are the rare forms of godlike cells called cancer stem cells are found in tumours and give rise to a wide range of cell types that make up the tumour. These cells have been identified in several human tumours and may serve as targets for cancer therapy. Most anti-cancer medications function by inducing the death of cancer cells. Even though these treatments seem to be working, some individuals nonetheless have a disease recurrence. The primary driver fuelling the expansion of the cancer stem cell market is the rising incidence of cancer in the world.

Impact of COVID-19 on the Global Cancer Stem Cells Market:

The cancer stem cell sector has prospered from the COVID-19 epidemic. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from originating stem cells, are two of the most significant strides in stem cell research during COVID-19. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from stem cells, have been two of the most important strides in stem cell research during COVID-19. This element had a favourable effect on the world market for cancer stem cells. Additionally, there has been an increase in the use of allogeneic stem cell therapy and hematopoietic cell transplantation (HCT), particularly among cancer patients who have COVID-19 infections.

Scope of the Report:

Report Metric Details:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Cancer, By Mode Of Action, By Transplantation, By Application, By End User
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: AbbVie Inc., Advanced Cell Diagnostics Inc., Bionomics, BioNTech, BioTime Inc., Caladrius Biosciences Inc., Celgene Corp., ExCellThera, Gamida Cell, Irvine Scientific, Lonza, MacroGenics, Inc., Menarini Group, Merck KGaA, Mereo BioPharma, Miltenyi, Biotec, PromoCell GmbH, Propanc Biopharma, Silicon Biosystems, Sino Biological Inc., Thermo Fisher Scientific Inc., ViaCyte Inc.

Global Cancer Stem Cells Market Segmentation:

  • By Caner: Based on the Caner, Global Cancer Stem Cells Market is segmented as; Acute Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Osteopetrosis.
  • By Mode Of Action: Based on the Mode Of Action, Global Cancer Stem Cells Market is segmented as; Targeted Cancerous Stem Cells {By Anti-CSC Therapeutics (Pathway Inhibitors, Surface Marker Based, Immuno-evasion and Targeting Tumour Microenvironment, Nanoparticle-based Therapies), Products (Cell-Culturing, Cell-Separation, Cell-Analysis, Molecular Analysis)}, Stem Cell Based Cancer Therapy (Autologous SC Transplant, Allogeneic SC Transplant).
  • By Transplantation: Based on the Transplantation, Global Cancer Stem Cells Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
  • By Application: Based on the Application, Global Cancer Stem Cells Market is segmented as; Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer.
  • By End User: Based on the End Use, Global Cancer Stem Cells Market is segmented as; Hospitals and surgical laboratories, Cell banks and tissue banks, Pharmaceutical and biomedical companies.
  • By Region: Due to improvements in healthcare infrastructure and strong reimbursement policies across the region, North America had the substantial share, accounting for more than two-fifths of the worldwide cancer stem cell market. On the other hand, the Asia-Pacific area will have the fastest growth in the following years. This is because the governments of China, Japan, and India are developing regulations for the development of stem cell research facilities and investing in healthcare infrastructure.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity, and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Cancer Stem Cells Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cancer Stem Cells Market, By Cancer, 2019-2032 (USD Million)

  • 6.1. Acute Leukemia
  • 6.2. Aplastic Anemia
  • 6.3. Chronic Lymphocytic Leukemia
  • 6.4. Osteopetrosis

7. Global Cancer Stem Cells Market, By Mode Of Action, 2019-2032 (USD Million)

  • 7.1 Targeted Cancerous Stem Cells
    • 7.1.1 By Anti-CSC Therapeutics
      • 7.1.1.1 Pathway Inhibitors
      • 7.1.1.2 Surface Marker Based
      • 7.1.1.3 Immuno-evasion and Targeting Tumour Microenvironment
      • 7.1.1.4 Nanoparticle-based Therapies
    • 7.1.2 Products
      • 7.1.2.1 Cell-Culturing
      • 7.1.2.2 Cell-Separation
      • 7.1.2.3 Cell-Analysis
      • 7.1.2.4 Molecular Analysis
  • 7.2 Stem Cell Based Cancer Therapy
    • 7.2.1 Autologous SC Transplant
    • 7.2.2 Allogeneic SC Transplant

8. Global Cancer Stem Cells Market, By Transplantation, 2019-2032 (USD Million)

  • 8.1. Allogeneic Stem Cell Therapy
  • 8.2. Autologous Stem Cell Therapy

9. Global Cancer Stem Cells Market, By Application, 2019-2032 (USD Million)

  • 9.1. Blood Cancer
  • 9.2. Breast Cancer
  • 9.3. Cervical Cancer
  • 9.4. Colorectal Cancer
  • 9.5. Lung Cancer
  • 9.6. Prostate Cancer

10. Global Cancer Stem Cells Market, By End Use, 2019-2032 (USD Million)

  • 10.1 Cell Banks and Tissue Banks
  • 10.2 Hospital and Surgical Laboratories
  • 10.3 Pharmaceutical and Biomedical Companies

11. Global Cancer Stem Cells Market, By Region, 2019-2032 (USD Million)

  • 11.1 North America
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Mexico
  • 11.2 Europe
    • 11.2.1. Germany
    • 11.2.2. United Kingdom
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Australia
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4 South America
    • 11.4.1. Brazil
    • 11.4.2. Argentina
    • 11.4.3. Rest of South America
  • 11.5 Middle East & Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Rest of Middle East & Africa

12. Company Profiles

  • 12.1 AbbVie Inc.
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2 Advanced Cell Diagnostics Inc.
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3 Bionomics
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4 BioNTech
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5 BioTime Inc.
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6 Caladrius Biosciences Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7 Celgene Corp.
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8 ExCellThera
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9 Gamida Cell
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10 Irvine Scientific
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11 Lonza
    • 12.11.1. Company details
    • 12.11.2. Financial outlook
    • 12.11.3. Product summary
    • 12.11.4. Recent developments
  • 12.12 MacroGenics Inc.
    • 12.12.1. Company details
    • 12.12.2. Financial outlook
    • 12.12.3. Product summary
    • 12.12.4. Recent developments
  • 12.13 Menarini Group
    • 12.13.1. Company details
    • 12.13.2. Financial outlook
    • 12.13.3. Product summary
    • 12.13.4. Recent developments
  • 12.14 Merck KGaA
    • 12.14.1. Company details
    • 12.14.2. Financial outlook
    • 12.14.3. Product summary
    • 12.14.4. Recent developments
  • 12.15 Mereo BioPharma
    • 12.15.1. Company details
    • 12.15.2. Financial outlook
    • 12.15.3. Product summary
    • 12.15.4. Recent developments
  • 12.16 Miltenyi Biotec
    • 12.16.1. Company details
    • 12.16.2. Financial outlook
    • 12.16.3. Product summary
    • 12.16.4. Recent developments
  • 12.17 PromoCell GmbH
    • 12.17.1. Company details
    • 12.17.2. Financial outlook
    • 12.17.3. Product summary
    • 12.17.4. Recent developments
  • 12.18 Propanc Biopharma
    • 12.18.1. Company details
    • 12.18.2. Financial outlook
    • 12.18.3. Product summary
    • 12.18.4. Recent developments
  • 12.19 Silicon Biosystems
    • 12.19.1. Company details
    • 12.19.2. Financial outlook
    • 12.19.3. Product summary
    • 12.19.4. Recent developments
  • 12.20 Sino Biological Inc.
    • 12.20.1. Company details
    • 12.20.2. Financial outlook
    • 12.20.3. Product summary
    • 12.20.4. Recent developments
  • 12.21 Thermo Fisher Scientific Inc.
    • 12.21.1. Company details
    • 12.21.2. Financial outlook
    • 12.21.3. Product summary
    • 12.21.4. Recent developments
  • 12.22 VIaCyte Inc.
    • 12.22.1. Company details
    • 12.22.2. Financial outlook
    • 12.22.3. Product summary
    • 12.22.4. Recent developments